COVID-19 mRNA Vaccines and Improved Response to Immunotherapy
November 2, 2025
Introduction Data from a new MD Anderson study that was presented at ESMO 2025 and published in Nature entitled “SARS-CoV-2…
The Immunotherapy 360 blog space features articles that encompass prominent issues related to immunotherapy. These are written with the assistance of the staff at AIM at Melanoma, AIM with Immunotherapy and health care practitioners.
If you have an idea for a future article, please reach out to us on our contact page!
Cytokine Release Syndrome
October 22, 2025
Introduction The approval and availability of cancer immunotherapies have significantly advanced treatment outcomes for patients with melanoma and with other…
Regeneron Announces Approval of Cemiplimab-rwlc for Adjuvant Treatment of Cutaneous Squamous-Cell Carcinoma with a High Risk of Recurrence After Surgery and Radiation
October 9, 2025
The first and only FDA-approved immunotherapyfor this patient population October 8, 2025 (Sacramento, California) The FDA has approved the PD-1…
Subcutaneous Versus Intravenous Nivolumab Formulations: Important Considerations for Patient Care
September 23, 2025
In December 2024, the FDA approved a subcutaneous formulation of the immune checkpoint inhibitor nivolumab across adult, solid tumor nivolumab…
Anti-TIGIT Immunotherapy in Melanoma
September 1, 2025
Checkpoint Inhibitor Therapies and Unmet Needs Checkpoint inhibitor therapies have been a major advance for patients with melanoma. Recent long-term…
A Strategy Aimed at Reducing the Toxicity Associated with TIL Therapy
August 24, 2025
Introduction Tumor-infiltrating lymphocyte (TIL) therapy, such as lifileucel, is approved for use in adults with unresectable, advanced melanoma that has…
Observations Learned from Steroid Use to Manage Immune-Related Adverse Events (irAEs)
August 6, 2025
Helping an individual’s immune system to re-recognize and identify cancer cells has proven to be the most effective drug strategy…
Experiencing the Worst Effects Indicates the Best News for Patients
June 4, 2025
The silver lining for patients experiencing side effects related to immunotherapy and targeted therapy for cancer treatment is that these…
What’s the Issue of Concurrent Statins During Immune Checkpoint Inhibitor Therapy?
May 28, 2025
Introduction Recently, published studies have sparked discussion about combining statins with immune checkpoint inhibitors during cancer treatment. The Journal of…
Ocular Toxicities Associated with Vedotins and Other Antibody-Drug Conjugates are Manageable
April 23, 2025
Introduction In recent years, several antibody-drug conjugates have received approval for the treatment of gynecological cancers, adding powerful tools to…